(Total Views: 725)
Posted On: 10/21/2020 8:20:36 PM
Post# of 148908
This PR got lost in the fog yesterday. Nice affirmation of last week's CYDY PR on the Philippines:
Under the partnership, CytoDyn will maintain responsibility for the development of leronlimab, while Chiral has agreed to help the biotech firm obtain FDA approval to make the drug available to the Filipino people.
By bringing this innovative drug to the Philippines, Chiral Pharma aims to help decrease the number of COVID-19 patients progressing to more severe cases in the country. “Companies across the globe are tirelessly developing medicines and vaccines to treat COVID-19. As CytoDyn has been working hard to complete the third phase of the clinical trial, we are committed to supporting the registration of leronlimab with the FDA in the Philippines. We are hoping the drug will greatly help our patients recover and have another chance at life,” Dr. Francis Z. Gomez, President and CEO said.
Under the partnership, CytoDyn will maintain responsibility for the development of leronlimab, while Chiral has agreed to help the biotech firm obtain FDA approval to make the drug available to the Filipino people.
By bringing this innovative drug to the Philippines, Chiral Pharma aims to help decrease the number of COVID-19 patients progressing to more severe cases in the country. “Companies across the globe are tirelessly developing medicines and vaccines to treat COVID-19. As CytoDyn has been working hard to complete the third phase of the clinical trial, we are committed to supporting the registration of leronlimab with the FDA in the Philippines. We are hoping the drug will greatly help our patients recover and have another chance at life,” Dr. Francis Z. Gomez, President and CEO said.
(4)
(0)Scroll down for more posts ▼
